Find comprehensive information on Chronic Myelocytic Leukemia (CML), also known as Chronic Myeloid Leukemia. This resource covers CML diagnosis, symptoms, treatment, and prognosis. Learn about relevant healthcare, clinical documentation, and medical coding terms for accurate and efficient medical record keeping related to Chronic Myelocytic Leukemia. Explore information on CML lab tests, diagnostic criteria, and ICD codes for optimal clinical documentation and medical coding practices.
Also known as
Chronic myeloid leukemia, BCR/ABL-positive
Chronic myeloid leukemia characterized by the presence of the Philadelphia chromosome or BCR/ABL fusion gene.
Chronic myeloid leukemia, atypical
Chronic myeloid leukemia that doesn't fit the typical BCR/ABL-positive presentation.
Chronic myeloid leukemia, NOS
Chronic myeloid leukemia not otherwise specified.
Acute myeloid leukemias
While distinct, CML can transform into acute myeloid leukemia (AML), making this a relevant related category.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the CML in blast phase?
When to use each related code
| Description |
|---|
| Slowly progressing blood cancer of bone marrow. |
| Group of cancers affecting bone marrow and blood. |
| Rare, fast-growing blood cancer affecting bone marrow. |
Miscoding CML (C92.1) as CLL (C91.1) due to similar names and abbreviations, impacting data accuracy and reimbursement.
Failing to specify blast phase (C92.11, C92.12) when present, leading to undercoding severity and incorrect treatment plans.
Using unspecified CML code (C92.10) when more specific documentation is available, hindering accurate case-mix analysis and resource allocation.
Q: What are the most recent advancements in frontline treatment strategies for chronic myeloid leukemia (CML) in the chronic phase?
A: Recent advancements in frontline treatment for chronic phase CML primarily focus on tyrosine kinase inhibitors (TKIs). Second-generation TKIs like nilotinib, dasatinib, and bosutinib have demonstrated higher rates of deeper molecular responses compared to imatinib, the first-generation TKI. Choosing the optimal TKI involves considering factors such as patient comorbidities, potential side effects, and resistance profiles. Furthermore, research is exploring TKI-free remission strategies in select patients achieving sustained deep molecular responses. Consider implementing a risk-stratified approach to CML management based on the latest ELN recommendations. Explore how advancements in molecular monitoring are shaping treatment decisions and influencing the potential for treatment-free remission. Learn more about the latest clinical trial data comparing the efficacy and safety profiles of various TKIs.
Q: How do I differentiate between accelerated phase CML and blast phase CML in clinical practice, and what are the key diagnostic criteria involved?
A: Differentiating accelerated phase (AP-CML) and blast phase (BP-CML) requires careful evaluation of blood counts, bone marrow morphology, and cytogenetics. AP-CML is characterized by persistent or increasing blasts (10-19% in blood or bone marrow), basophilia (>=20%), thrombocytopenia (<100 x 10^9/L unrelated to therapy), and/or the development of additional chromosomal abnormalities in Philadelphia chromosome-positive cells. BP-CML is defined by >=20% blasts in blood or bone marrow or the development of extramedullary blast proliferation. Accurate diagnosis is crucial as it signifies disease progression and necessitates a shift to more aggressive treatment strategies. Consider implementing a multidisciplinary approach involving hematopathologists and cytogeneticists to ensure accurate diagnosis and staging. Explore how advancements in flow cytometry and molecular diagnostics can further refine the characterization of these disease phases.
Patient presents with findings suggestive of Chronic Myelocytic Leukemia (CML), also known as Chronic Myeloid Leukemia. Symptoms include fatigue, splenomegaly, weight loss, and night sweats. Physical examination reveals palpable splenomegaly. Complete blood count (CBC) demonstrates leukocytosis with a predominance of myeloid cells at various stages of maturation, including myelocytes, metamyelocytes, and band forms. A peripheral blood smear confirms the presence of immature myeloid cells. Bone marrow biopsy and aspirate reveal hypercellular marrow with granulocytic hyperplasia and the presence of the Philadelphia chromosome, confirming the diagnosis of CML. Molecular testing demonstrates the BCR-ABL fusion gene. Based on these findings, the patient is diagnosed with chronic phase CML. Differential diagnosis includes other myeloproliferative neoplasms such as essential thrombocythemia, polycythemia vera, and primary myelofibrosis. Treatment plan includes tyrosine kinase inhibitor (TKI) therapy with imatinib mesylate as first-line treatment. Patient education provided regarding CML prognosis, treatment options including allogeneic stem cell transplantation, and potential side effects of TKI therapy. Follow-up appointments scheduled for monitoring of treatment response, including complete blood counts, BCR-ABL transcript levels, and assessment of potential adverse events. ICD-10 code C92.1 is assigned for Chronic Myeloid Leukemia, BCR-ABL positive. Medical billing codes will reflect evaluation and management services, laboratory testing, bone marrow biopsy, and pharmacologic management. Genetic counseling is recommended. The patient understands the diagnosis and treatment plan.